



ROBERT KOCH INSTITUT



Final Program



6th International Conference on Tularemia
13–16 September 2009 | Berlin, Germany
Charité Campus Mitte (CCM)

www.tularemia-network.com

WELCOME ADDRESS	4
CONTACT INFORMATION / ORGANIZING COMMITTEE	5
MAP OF THE CHARITÉ	6
SCIENTIFIC INFORMATION / LEGEND	7
IMPRINT	7
 SCIENTIFIC PROGRAM PER DAY	
Sunday, 13 September	8
Monday, 14 September	14
Tuesday, 15 September	22
Wednesday, 16 September	26
 ACKNOWLEDGEMENTS	28
GENERAL INFORMATION	29
BERLIN INFORMATION	30
SOCIAL AND SUPPORTING PROGRAM	31
 ABSTRACTS	
Sunday, 13 September	32
Monday, 14 September	85
Tuesday, 15 September	161
Wednesday, 16 September	179
 LIST OF PARTICIPANTS	188
INDEX OF AUTHORS	196

The **6th International Conference on Tularemia** will be held at Charité, Berlin, from 13 to 16 September 2009. This university hospital complex combines a long history, beginning in 1710 as “Plague-House”, with today’s very modern achievements. After the re-unification of Germany in 1989, the Charité became the medical school for both the Humboldt University and the Free University of Berlin. With four campuses, it is one of the largest university hospitals in Europe with 15,000 employees and 8,000 students.

It is also the place where many famous physicians and scientists have worked or studied for at least part of their academic lives, such as the Nobel Prize winners Emil Adolf von Behring (1854–1917), Paul Ehrlich (1854–1915), and Rudolf Virchow (1821–1902). In particular, the microbiologist Robert Koch (1843–1910) must be mentioned since the 100th anniversary of his death will be commemorated next year. Notably, Robert Koch established basic methods and approaches which later supported the discovery of *Francisella*. Therefore, the team of the Robert Koch-Institute is pleased to serve as the local organizers of the conference, and we cordially welcome all participants to Berlin.

As with all Tularemia conferences before, the **6th International Conference on Tularemia** hopes to be a top forum for the exchange of knowledge about tularemia and its causative agent, *Francisella tularensis*, and of all aspects of clinical, applied and fundamental research. Over the years since the first conference, the interest in this disease and its causative agent has been steadily growing. In addition to raised awareness because of the agent’s possible intentional usage, in some regions of the world it also causes epidemics and affects humans and animals. There is a real need to understand the pathology and biological mechanisms of infection, as well as the epidemiology and ecology of these bacteria, in order to develop new treatments and vaccines. Moreover, *Francisella* is a fascinating model organism for studying the behaviour of facultative intracellular bacteria in interaction with their target cells.

This interest and the increasing need for communication, exchange of experience and materials, and training in diagnostics and research methods has led to the idea of creating a Tularemia International Society. Under the umbrella and with active participation of WHO, a group of scientists has met twice in Berlin at the Robert Koch-Institute to develop this idea. We would like to use this conference to further discuss the idea of a Tularemia Society, with a view to taking the first steps towards launching this Society.

The comprehensive program of the **6th International Conference on Tularemia** is the result of the input by the Tularemia community and the intensive work of the Scientific Committee. We are looking forward to an exciting and useful conference that will provide the platform for new ideas, and serve as a gathering of colleagues and friends.

On behalf of the Scientific Committee and the Local Organizing Committee



Roland Grunow

LOCAL ORGANIZING COMMITTEE

Chairman

Dr. Roland Grunow

Robert Koch-Institute

Nordufer 20
13353 Berlin

Email: GrunowR@rki.de
Phone: +49 (0)30 187 54 2100

Local Organizing Committee Members

Dr. Daniela Jacob
Email: JacobD@rki.de

Dr. Sonja Kiessling
Email: KiesslingS@rki.de

Secretary


Anna Rohleder
Email: RohlederA@rki.de

PCO

MCI – Berlin Office

MCI Deutschland GmbH
Markgrafenstr. 56
10117 Berlin, Germany

Phone: +49 (0)30 20 45 90
Fax: +49 (0)30 2045 950
Email: info@tularemia-network.com



The congress program is structured thematically and within the scientific program section chronological per day.

LEGEND

- PLENARY SESSIONS
- SYMPOSIA
- POSTER SESSIONS
- ROUND TABLE DISCUSSION
- TULAREMIA INTERNATIONAL SOCIETY

IMPRINT

Publisher:
Robert Koch-Institute, Nordufer 20, 13353 Berlin, Germany

Editorial:
Local Organizing Committee and MCI – Berlin Office

Layout & Graphics:
ETEPETETE Group, A. Kusserow, Berlin, Germany

Photos:
Brandenburg Gate © Roland Grunow, Berlin, Germany
Robert Koch-Institute © Robert Koch-Institute, Berlin, Germany
TV Tower © Berlin Partner/FTB-Werbefotografie

Printing:
LASERLINE, Digitales Druckzentrum, Bucec & Co. Berlin KG
Scheringstraße 1, 13355 Berlin, Germany

Sunday, 13 Sep

Monday, 14 Sep

Tuesday, 15 Sep

Wednesday, 16 Sep

TIME	AUDITORIUM	FOYER
09.30 – 11.00 h		Registration Poster Installation of Poster Session 1
11.00 – 12.20 h	Opening Session	
12.20 – 13.30 h		Lunch
13.30 – 15.00 h	S1 – Genomics / Proteomics / Genetics of <i>Francisella</i>	
15.00 – 15.30 h		Coffee
15.30 – 17.00 h	S2 – Virulence factors associated with intracellular growth of <i>Francisella</i>	
17.00 – 19.30 h	Poster Viewing Part 1	Get-Together
19.30 – 20.15 h	Interactive Round Table Discussion – Comparative Biology of Intracellular Growth	

11.00 – 12.20 h AUDITORIUM

Opening Session – Welcome Address

Opening and Welcome Notes

Jörg Hacker, President of the Robert Koch-Institute (Germany)

The Idea of a Tularemia International Society

May Chu, WHO (Switzerland)

Introduction of the Keynote Speaker

Roland Grunow, Robert Koch-Institute (Germany)

The present and future *Francisella* research

Anders Sjöstedt, University of Umeå (Sweden)

13.30 – 15.00 h AUDITORIUM

S 1 – Genomics / Proteomics / Genetics of *Francisella*

Chairs: Anders Sjöstedt, University Umeå (Sweden)
Vitaly Pavlov, SRC for AMB Obolensk (Russia)

Characterization of an essential virulence factor

Barbara Mann, University of Virginia (USA)

25 min

Macrophage screen identifies *Francisella* genes required for intracellular replication

David Weiss, Emory University (USA)

25 min

Determining the function of the cytoplasmic membrane protein RipA

Brittany Mortensen, University of North Carolina-Chapel Hill (USA)

20 min

Attenuation and protective efficacy of live vaccine strain mutants deficient in capsule-like material

Anna Champion, Virginia Polytechnic and State University (USA)

20 min

15.30 – 17.00 h AUDITORIUM

S 2 – Virulence Factors Associated with Intracellular Growth of *Francisella*

Chairs: Francis Nano, University of Victoria (Canada)
Alain Charbit, Université Paris Descarte (France)

Intracellular nutrition and *F. tularensis* pathogenesis

Alain Charbit, Université Paris (France)

25 min

Sunday, 13 Sep

Monday, 14 Sep

Tuesday, 15 Sep

Wednesday, 16 Sep

- Type 6 Secretion in *Francisella*?**
Francis Nano, University of Victoria (Canada) 25 min
- Francisella novicida* and innate immune surveillance mechanisms**
Denise Monack, Stanford University (USA) 20 min
- Role of Type IV pilin genes in virulence of *Francisella tularensis* subspecies *holarctica* and *tularensis***
Anna-Lena Forslund, FOI Swedish Defence Research Agency (Sweden) 20 min

17.30 – 19.00 h

FOYER

P1 – Poster Viewing Part 1

Molecular Analyses and Epidemiology/Persistence and Disease Control

- P1-01 A constraints-based systems approach to metabolic analysis of *Francisella tularensis* during infection**
Simon Daefler, Mount Sinai School of Medicine (United States)
- P1-03 *Francisella novicida* as a model to study tick transmission**
Susan Noh, USDA-Agriculture Research Service (United States)
- P1-04 Molecular typing of *Francisella tularensis* strains isolated in Georgia**
Gvantsa Chanturia, National Center for Disease Control and Public Health (Georgia)
- P1-05 Phenotypical analysis of the putative 2nd polysaccharide gene cluster of *Francisella tularensis***
Rebecca Thomas, Dstl Porton Down (United Kingdom)
- P1-06 Effect of Hfq on *Francisella tularensis* growth and stress resistance**
Jacob Chambers, Southern Illinois University (United States)
- P1-07 Analysis of membrane protein complexes of *F. tularensis* and their response to iron restriction studied by Blue native PAGE and DIGE**
Jana Klimentova, University of Defence, Faculty of Military Health Sciences (Czech Republic)
- P1-08 Production of outer membrane vesicles and tube-like structures by *Francisella tularensis***
William McCaig, Stony Brook University (United States)
- P1-09 The phosphoproteome of pathogenic bacterium *Francisella tularensis***
Petra Spidlova, University of Defence, Faculty of Military Health Sciences (Czech Republic)
- P1-10 Comparative proteome analysis of *Francisella tularensis* LVS and DsbA deletion mutant: identification of potential substrate proteins for the DsbA**
Ivona Pavkova, Faculty of Military Health Science, University of Defence (Czech Republic)

- P1-11 Analysis of the phenotype associated with the disruption of *mgIA* in *Francisella tularensis* LVS underlines its central role in manifestation of virulence**
Galia Zaide, Israel Institute for Biological Research (Israel)
- P1-12 Mapping the presence of *Francisella tularensis* glycoproteins**
Lucie Balonova, University of Defence (Czech Republic)
- P1-13 The only alternative σ factor of *Francisella tularensis* is a genuine heat shock σ factor**
Karin Meibom, Université Paris V René Descartes (France)
- P1-14 Genotyping of the Health Protection Agency *Francisella* strain collection**
Jennie Latham, Health Protection Agency (United Kingdom)
- P1-15 A screen of screens: Genes required for intracellular replication vs. *in vivo* virulence**
Anna Llewellyn, Emory University (United States)
- P1-16a Identification and differentiating of *Francisella* by metabolic profiling**
William Dorman, U.S. Army Medical Research Institute of Infectious Diseases, USAMRIID (United States)
- P1-16b Characterization of the secreted effector protein IgIC in *Francisella tularensis* virulence**
Jeffrey Barker, University of Texas at San Antonio / South Texas Center for Emerging Infectious Diseases (United States)
- P1-17 Carbon substrate utilization patterns for the phenotypic differentiation between *Francisella* species and *Francisella tularensis* subspecies**
Martin Weber, Bundeswehr Institute of Microbiology (Germany)
- P1-18 Non-antibiotic selectable markers for *Francisella tularensis* strains LVS and SchuS4**
Stephanie Smith, Battelle Memorial Institute (United States)
- P1-19 *Francisella tularensis* requires FeoB for acquisition of iron, intracellular growth, and virulence**
Huaxin Zheng, Stony Brook University (United States)
- P1-20 A surface exposed protein encoded by *ftt1103* mediates internalization of *F. tularensis* SchuS4 into host cells**
Aiping Qin, University of Virginia (United States)
- P1-21 Results from screening the *F. novicida* transposon two-allele mutant library**
Xin-He Lai, Oregon Health Science Univeristy (United States)
- P1-22 Identification of *Francisella* loci that impact expression of *ripA***
Todd Kijek, University of North Carolina (United States)
- P1-23 Small molecule control of virulence gene expression in *Francisella tularensis***
James Charity, Harvard Medical School (United States)
- P1-24 Siderophore utilization in *Francisella tularensis* Live Vaccine Strain (LVS)**
Girija Ramakrishnan, University of Virginia (United States)

- P1-25 Use of a *Galleria mellonella* alternative host system for the identification of *Francisella* virulence factors**
Nathan Fisher, United States Army Medical Research Institute of Infectious Disease (United States)
- P1-26 Identification of *Francisella tularensis* live vaccine strain CuZn superoxide dismutase as critical for resistance to H host generated reactive oxygen/nitrogen species**
Chandra Bakshi, Albany Medical College (United States)
- P1-27 *Francisella* secretes proteins encoded in the Pathogenicity Island**
Rebekah Hare-Sanford, University of Alaska Fairbanks (United States)
- P1-28 Type IV pilin-like proteins of *Francisella tularensis* contribute to virulence in a context-dependent manner**
Nicole Ark, University of Virginia (United States)
- P1-29 Comparison of mutational patterns of laboratory and naturally propagated *F. tularensis* strains**
Andreas Sjödin, FOI – Swedish Defence Research Agency (Sweden)
- P1-30 Membrane lipoproteins in *Francisella tularensis* ssp. *holarctica* pathogenicity**
Adela Straskova, University of Defence, Faculty of Military Health Sciences (Czech Republic)
- P1-31 Analysis of proteins of *Francisella tularensis* in the site of infection by laser microdissection and tandem mass spectrometry**
Martin Hubalek, University of Defence (Czech Republic)
- P1-32 Protein secretion via outer membrane vesicles in *F. tularensis***
Klara Konecna, Faculty of Military Health Science, University of Defence (Czech Republic)
- P1-33 Identification of *Francisella* genes required for virulence and escape into the cytoplasm of macrophages**
Rexford Asare, University of Louisville (United States)
- P1-34 Validation of Etest® for the determination of antibiotic susceptibilities of *Francisella tularensis***
Eric Valade, IRBA/CRSSA (France)
- P1-35 Tularemia wet-lab exercise**
Mats Forsman, Sweden Defence Research Agency (Sweden)
- P1-36 Development of reference material to perform proficiency tests for the diagnosis of highly pathogenic bacteria, including *Francisella tularensis***
Uschi Sauer, Robert Koch-Institute (Germany)
- P1-37 Rapid identification of *Francisella tularensis* by pyrosequencing of a 16S rDNA fragment**
Benjamin Edvinsson, Swedish Institute for Infectious Disease Control, SMI (Sweden)
- P1-39 Therapy approach and problems in treatment tularemic patients in Serbia**
Marina Djordjevic, Clinical Center University of Nis (Serbia)

- P1-40 Detection of *Francisella tularensis* in the European hare by real-time TaqMan PCR**
Nora Madani, French Food Safety Agency (AFSSA) (France)
- P1-41 Antimicrobial susceptibility patterns of *Francisella* species from Central Europe with standardized broth microdilution testing**
Enrico Georgi, Bundeswehr Institute of Microbiology (Germany)
- P1-42 Prolonged course of tick-borne ulceroglandular tularemia in a 20-year-old patient in Germany – case report**
Christoph Luebbert, Martin Luther University Halle-Wittenberg (Germany)
- P1-43 First isolation of *Francisella tularensis* subspecies *holarctica* from foxes (*Vulpes vulpes*) in Germany**
Herbert Nattermann, Robert Koch-Institute (Germany)
- P1-44 Evaluation of an immunochromatographic test (ICT) for the rapid and reliable serodiagnosis of human tularemia and the detection of anti-*F. tularensis* antibodies in serum from different mammalian species**
Wolf Spletstoesser, Bundeswehr Institute of Microbiology (Germany)
- P1-45 Enhanced growth of *Francisella tularensis* in a liquid nutrient medium (medium T)**
Daniela Jacob, Robert Koch-Institute (Germany)
- P1-46 Prevalence of *Francisella tularensis* in European brown hare populations in Lower Saxony, Germany**
Martin Runge, LAVES – Veterinary Institute Hannover (Germany)

19.30 – 20.15 h

AUDITORIUM

Interactive Round-Table Discussion Comparative Biology of Intracellular Growth

Chairs: Marcus Horwitz, UCLA (USA)
Discussants: Marcus Horwitz, UCLA (USA)
 Yousef Abu-Kwaik, University of Louisville (USA)
 Karsten Hueffer, University of Alaska Fairbanks (USA)

TIME	AUDITORIUM	FOYER
08.30 – 09.00 h		Removal of Posters from Poster Session 1
09.00 – 10.30 h	S3 – Molecular and Biochemical Analysis of <i>Francisella</i>	
10.30 – 11.00 h		Coffee
11.00 – 12.15 h	S4 – Short Presentations	
12.15 – 13.30 h		Lunch
		Poster Installation of Poster Session 2
13.30 – 15.00 h	S5 – Molecular Epidemiology, Population Genetics and Taxonomy of <i>Francisella</i>	
15.00 – 15.30 h		Coffee
15.30 – 16.40 h	S6 – Molecular mechanisms for <i>F. tularensis</i> persistence and targets for disease control	
16.50 – 17.30 h	Meeting on Formation of the Tularemia International Society	
17.30 – 20.00 h	Poster Viewing Part 2	Get-Together

09.00 – 10.30 h AUDITORIUM

S 3 – Molecular and Biochemical Analysis of *Francisella*

Chairs: Karl Klose, University of Texas at San Antonio (USA)
Petra Oyston, Defence Science and Technology Laboratory, DSTL (United Kingdom)

The *Francisella tularensis* Pathogenicity Island Encodes a Secretion System that is required for Phagosome Escape and Virulence

Karl Klose, University of Texas at San Antonio (USA) 25 min

Small molecule control of *Francisella* virulence gene expression

Simon Dove, Harvard Medical School (USA) 25 min

Global regulation in *Francisella tularensis*

Petra Oyston, Defence Science and Technology Laboratory, DSTL (United Kingdom) 20 min

A genome-scale phenotype map of *Francisella novicida*

Colin Manoil, University of Washington (USA) 20 min

11.00 – 12.15 h AUDITORIUM

S 4 – Short Presentations

Chairs: May Chu, WHO (Switzerland)
Sam Telford, Tufts University (USA)

Heterologous expression of *Francisella tularensis* type IV pili genes in *Neisseria gonorrhoeae* confirms that PilA can form functional pili

Emelie Salomonsson, FOI – CBRN Defence and Security (Sweden) 15 min

Identification of *F. tularensis* from environmental water specimens in tularemia epidemics in Turkey by both culture and real time TaqMan PCR methods

Aynur Karadenizli, Kocaeli University Medical Faculty (Turkey) 15 min

Characterization of a novel *Francisella* sp. from blood and urine of a patient with an unusual clinical presentation

Raquel Escudero, National Center of Microbiology, ISCIII (Spain) 10 min

Description of '*Francisella novicida*' FSC454^T as a novel species of the genus *Francisella*

Hans-Jürgen Busse, Institute of Bacteriology, Mycology & Hygiene se (Austria) 10 min

Identification of potential tularemia biomarkers from *Francisella* infected plasma

James Chambers, University of Texas at San Antonio (USA) 15 min

13.30 – 15.00 h

AUDITORIUM

S 5 – Molecular Epidemiology, Population Genetics and Taxonomy of *Francisella*

Chairs: Anders Johansson, University Umeå, FOI (Sweden)
Raquel Escudero, Instituto de Salud Carlos III (Spain)
Fang Zhang, Beijing Institute of Microbiology and Epidemiology (China)

Phylogeography of *Francisella tularensis*: Whole genome sequences and SNP analysis defining the clade and lineage structure of a highly clonal complex

Paul Keim, Northern Arizona University (USA) 25 min

A1b, a subpopulation of *F. tularensis* subsp. *tularensis* associated with mortality in humans

Jeannine Petersen, Centers for Disease Control and Prevention (USA) 25 min

A radical change in bacterial population structure was linked to the evolution of *Francisella tularensis*

Pär Larsson, Swedish Defence Research Agency, FOI (Sweden) 20 min

Clash of clones? Distinct geographical distribution of an emerging subclone of *Francisella tularensis holarctica* in Germany and Central Europe

Wolf Splettstoesser, Bundeswehr Institute of Microbiology (Germany) 20 min

15.30 – 16.40 h

AUDITORIUM

S 6 – Molecular Mechanisms for *F. tularensis* Persistence and Targets for Disease Control

Chairs: Mats Forsman, FOI (Sweden)
Jeannine Petersen, Centers for Disease Control (USA)

QseC-inhibitors as potential therapeutics to *Francisella tularensis*

Vanessa Sperandio, UT Southwestern Medical Center (USA) 25 min

Environmental amoebae as potential reservoirs for *Francisella tularensis*:

Identification of molecular determinants of environmental persistence
Amy Rasley, Lawrence Livermore National Laboratory (USA) 25 min

Interaction of mosquito larvae with *Francisella tularensis* LVS biofilms

Tamara McNealy, Clemson University, Biological Sciences (USA) 20 min

16.50 – 17.30 h

AUDITORIUM

Meeting on Formation of the Tularemia International Society

- Presentation of Board Candidates
- Formalities
- Election of the Board

17.30 – 20.00 h

FOYER

P2 – Poster Viewing Part 2

Epidemiology and Ecology / Cell Biology / Host Response and Vaccines

P2-01 *Francisella* Sec secretion contributes to attachment during biofilm formation and chitin colonization

Jeffrey Margolis, Stanford University (United States)

P2-03 Evaluation of the vector competence of *Dermacentor variabilis* (American dog tick) for transmission of *Francisella tularensis*

Sara Reese, Centers for Disease Control and Prevention (United States)

P2-05 Isolation of *Francisella tularensis* from mandibular lymph nodes of red foxes indicates active natural foci in Austria

Erwin Hofer, Institute for Veterinary Disease Control in Mödling, Austrian Agency for Health and Food Safety (AGES), (Austria)

P2-06 Association and uptake of *Francisella tularensis* subspecies *holarctica* into mosquitoes

Peter Mathisen, Swedish Defence Research Agency (FOI) and Umeå University (Sweden)

P2-07 Tularemia distribution 1924 – 1974 – Review of tularemia infections in man researched from published reports, local and national Infectious Disease notification systems

Andrew Pearson, Health Protection Agency (United Kingdom)

P2-08 Extra- and intracellular proliferation of *Francisella tularensis* (LVS) in presence of amoebae

Roland Grunow, Robert Koch-Institute (Germany)

P2-09 Application of multiple-locus variable number tandem repeat analysis (MLVA) for subtyping of Swedish isolates of *Francisella tularensis*

Tara Wahab, Swedish Institute for Infectious Disease Control (Sweden)

P2-10 An outbreak of tularaemia in Tuscany, Central Italy, linked to a natural spring water

Massimo Fabbri, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (Italy)

P2-11 Development of a Multiple-Locus Variable number of tandem repeat Analysis (MLVA) for Chinese *Francisella tularensis* and its application to some strains

Fang Zhang, The Center for Disease Control and Prevention of Lanzhou Command (China)

P2-12 *Francisella*-like endosymbiont in *Dermacentor reticulatus* collected in North of Portugal

Isabel Lopes de Carvalho, Instituto Nacional de Saúde Dr. Ricardo Jorge (Portugal)

P2-13 Longterm follow up of a natural focus of tularemia in south-west Slovakia

Vanda Výrosteková, Comenius University, Medical Faculty (Slovakia)

Acknowledgements: This work was supported by grants VEGA 1/4281/07, 2/7020/7 and APVT-51-004702

- P2-14** **The course of tularemia in Kosovo since the first outbreak in 1999**
Roland Grunow, Robert Koch-Institute (Germany)
- P2-15** **Epidemiologic situation in the occurrence of tularemia in Slovakia, 1997– 2008**
Vanda Výrosteková, Comenius University, Medical Faculty (Slovakia)
Acknowledgements: This work was supported by grants VEGA 1/4281/07 and APVT-51-004702 To
- P2-16** **Tularaemia seroprevalence studies under foxes and raccoon dogs in Germany**
Andrea Kuehn, Robert Koch-Institute (Germany)
- P2-17** **Monitoring the survival of fish *Francisella* pathogens in aquatic microcosms**
Samuel Duodu, National Veterinary Institute (Norway)
- P2-18** **Rodent population dynamics and human tularaemia epidemics: Historical perspective on the antiquity of tularaemia foci deduced from the association of lemming fever and tularemia-like disease in man and rodents**
Andrew Pearson, Health Protection Agency (United Kingdom)
- P2-19** **Descriptive epidemiology of tularaemia cases in two areas of Sweden during outbreaks between 1966 and 1973**
Andrew Pearson, Health Protection Agency (United Kingdom)
- P2-20** **Oropharyngeal tularemia – Clinical epidemiology of oropharyngeal tularemia in Scandinavia 1924 – 1974**
Andrew Pearson, Health Protection Agency (United Kingdom)
- P2-21** **A real-time PCR array for hierarchal identification of environmental and human pathogenic *Francisella***
Kerstin Svensson, Swedish Defence Research Agency (FOI) (Sweden)
- P2-22** **The role of functionally distinct T cell subsets and antibody in protection against pulmonary infections of *Francisella tularensis* Schu S4**
Rebecca Anderson, NIH/NIAID/LICP (United States)
- P2-23** **The efficacy of oral vaccination with a defined *Francisella* vaccine strain in inducing protective immunity against pneumonic tularemia**
Jieh-Juen Yu, University of Texas at San Antonio (United States)
- P2-24** ***Francisella tularensis* suppresses the proinflammatory response of endothelial cells via the endothelial protein C receptor**
DeAnna Bublitz, Stony Brook University (United States)
- P2-25** **Early immune responses to the Live vaccine strain and Schu S4 infection in cynomolgus macaques**
Amanda DuBois, University of New Mexico (United States)
- P2-26** **The pathology of *Francisella tularensis* Schu S4 in Cynomolgus macaques**
Julie Hutt, Lovelace Respiratory Research Institute (United States)

- P2-27** ***Francisella tularensis* targets protein kinase C-alpha to arrest phagosome maturation at a novel stage prior to compartment disruption and escape**
Lee-Ann Allen, University of Iowa (United States)
- P2-28** **T cell Epitope Identification in *F. tularensis***
Jeffrey Frelinger, University of North Carolina (United States)
- P2-29** **Characterization of aerosol infection with *F. tularensis* Schu S4 in cynomolgus macaques and LD₅₀determination**
Michelle Valderas, Lovelace Biomedical and Environmental Research Institute (United States)
- P2-30** **Innate immune signalling in response to *Francisella tularensis***
Richard Saint, DSTL (United Kingdom)
- P2-31** **Pyrin enhances IL-1 β processing and release in response to *Francisella***
Mikhail Gavrilin, The Ohio State University (United States)
- P2-32** **A partial screen for *Francisella tularensis* virulence determinants using *Drosophila melanogaster***
Svenja Stöven, Umeå University (Sweden)
- P2-33** **miR155 targets SHIP to enhance host response against *Francisella* infection**
Thomas Cremer, The Ohio State University (United States)
- P2-34** **The mode of phagocytic uptake determines *Francisella tularensis* subsp. *tularensis* Schu S4 intracellular fate**
Henriette Geier, Rocky Mountain Laboratories (United States)
- P2-35** **A novel role for *Francisella tularensis* antioxidant enzymes in modulating human macrophage signaling and activation**
Amanda Melillo, Albany Medical College (United States)
- P2-36** **A capsule-deficient mutant of *Francisella tularensis* live vaccine strain is significantly more attenuated than LVS yet induces comparable protection in mice against *F. tularensis* challenge**
Qingmei Jia, School of Medicine, University of California (United States)
- P2-37** **Intranasal Immunization with *Francisella tularensis* LPS and the TLR2 ligand PorB protect mice from pulmonary tularemia and is correlated with increased BALT in lungs of these mice**
Lee Wetzler, Boston University School of Medicine (United States)
- P2-40** **Analyses of phagocytic ability of rat macrophages for *Francisella tularensis***
Heather Ray, University of Texas at San Antonio (United States)
- P2-41** **Activation of apoptotic pathways in the course of B cell infection with *Francisella tularensis***
Zuzana Krocova, FMHS UoD (Czech Republic)

- P2-42** **The role of IL-17A in *F. tularensis* LVS infection**
Siobhan Cowley, FDA (United States)
- P2-43** **Depletion of dendritic cells impairs the innate response to *Francisella tularensis* LVS**
Samantha Roberts, FDA (United States)
- P2-44** **Passive immunization with immunoglobulin G protects against a lethal respiratory infection with type A *Francisella tularensis* in Fischer 344 rats**
Gopi Mara Koosham, University of New Mexico School of Medicine (United States)
- P2-45** **Importance of B cells in parenteral murine infection with *Francisella novicida***
Alicia Chou, FDA (United States)
- P2-46** **Dendritic cells serve as a vehicle for *Francisella tularensis* dissemination following airways infection**
Baruch Velan, Israel Institute for Biological Research (Israel)
- P2-47** **Full virulence is restored by reintroduction of two virulence loci into the live vaccine strain (LVS) of *Francisella tularensis***
Kerstin Kuoppa, FOI Swedish Defence Research Agency (Sweden)
- P2-48** **Advanced phage display – perspective approach for preparing of *Francisella tularensis* monoclonal antibodies**
Klara Kubelkova, University of Defence, Faculty of Military Health Sciences (Czech Republic)
- P2-49** **Optimization of aerosol generation techniques for *Francisella tularensis* LVS and Schu S4 strains**
Robert Sherwood, Lovelace Respiratory Research Institute (United States)
- P2-50** **Drosophila RNAi screen for host factors required for *Francisella tularensis* infection**
Christine Akimana, University of Louisville (United States)
- P2-51** **Development of a *Francisella tularensis* Schu S4 aerosol challenge model in the rhesus macaque**
H. Gelhaus, Battelle Biomedical Research Center (United States)
- P2-52** **Development and characterization of rodent and nonhuman primate inhalation exposure systems**
Kristopher Van Zandt, Battelle Biomedical Research Center (United States)
- P2-53** **Exposure of Swiss Webster mice to aerosolized *Francisella tularensis* Schu S4**
Kristopher Van Zandt, Battelle Biomedical Research Center (United States)
- P2-54** **Susceptibility to disease following intraperitoneal infection with *Francisella tularensis* differs between Fisher 344 and Sprague-Dawley rat strains**
Claudine Raymond, National Research Council of Canada, Canada,
- P2-55** **Protective efficacy of a *Francisella tularensis* type A complemented O-antigen mutant against murine tularemia**
Cheryl Ryder, Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech, Center for Molecular Medicine and Infectious Disease (United States)

- P2-56** ***Francisella tularensis* LVS fails to induce phagocytosis-induced cell death in human neutrophils and prolongs cell lifespan**
Justin Schwartz, University of Iowa (United States)
- P2-57** **A comparison of the host responses between humans and nonhuman primates to *Francisella tularensis* infection**
Luis DaSilva, USAMRIID (United States)
- P2-59** **Enhancing *Francisella tularensis* vaccine efficacy through stimulation of innate immunity**
Deanna Tarwacki, University of Pittsburgh (United States)
- P2-60** **Virulence comparisons between Schu S4 (A1a) and A1a, A1b, A2 and type B strains using temperature as a surrogate endpoint for death**
Claudia Molins, Centers for Disease Control and Prevention (United States)
- P2-61** **Evaluation of defined *Francisella tularensis* subsp. *tularensis* attenuated strains for vaccine efficacy in a murine model**
Karl Klose, University of Texas at San Antonio (United States)
- P2-62** **A hypothetical outer membrane lipoprotein of *Francisella novicida* mediates evasion of IFN- γ induced inhibition within murine macrophages**
Jieh-Juen Yu, University of Texas at San Antonio (United States)
- P2-63** **Binding of serum complement regulatory proteins to *Francisella***
Sunita Gulati, University of Massachusetts Medical School (United States)
- P2-64** **Phase shift; A novel path to *Francisella* vaccine development**
Guillermo Madico, Boston University Medical Center (United States)
- P2-65** **Characterization of a nonhuman primate aerosol exposure system for generation, delivery, and collection of *Francisella tularensis* DVC Schu S4**
Lawrence Wolfram, DynPort Vaccine Company LLC (United States)

TIME	AUDITORIUM	FOYER
09.00 – 10.30 h	S7 – Epidemiology and ecology of <i>F. tularensis</i>	
10.30 – 11.00 h		Coffee
11.00 – 12.15 h	S8 – Short Presentations	
12.15 – 13.30 h		Lunch
13.30 – 15.00 h	S9 – Cell Biology	
15.00 – 15.30 h		Coffee
15.30 – 17.20 h	S10 – Responses of host cells to <i>Francisella</i>	
19.30 – 23.00 h	Gala Dinner at TV Tower	

09.00 – 10.30 h AUDITORIUM

S 7 – Epidemiology and Ecology of *F. tularensis*

Chairs: Sam Telford, Tufts University (USA)
 Erik Bäck, Örebro Universital Hospital (Sweden)
 Lela Bakanidze, National Center for Disease Control and Medical Statistics (Georgia)

Tularemia Outbreak in Castilla y León, Spain, 2007: an update
Alberto Pérez Rubio, Regional Office for Public Health in Castilla y León (Spain) 25 min

Late summer mosquito abundance is associated with human outbreaks of tularemia in Dalarna, Sweden
Anders Johansson, Umeå University (Sweden) 25 min

Analysis of clinical manifestations of typhoidal/pulmonary tularaemia in an emergent area
Emma Löfström, Örebro University Hospital (Sweden) 20 min

Nonrandom mating among infected and uninfected *D. variabilis* in a natural focus: evidence for transovarial transmission?
Heidi Goethert, Tufts Cummings School of Veterinary Medicine (USA) 20 min

11.00 – 12.15 h AUDITORIUM

S 8 – Short Presentations

Chairs: Todor Kantardjiev, National Center of Infectious and Parasitic Diseases (Bulgaria)
 Roland Grunow, Robert Koch-Institute (Germany)

Fate of the complex formed between nucleolin present on membrane of human cells and LVS surface elongation factor Tu (EF-Tu) during LVS infection
Monique Barel, Université Paris V René Descartes (France) 15 min

Differences in virulence between subspecies of *Francisella tularensis* are reflected in different gene expression profiles of human neutrophils
Erik Seibold, Bundeswehr Institute of Microbiology (Germany) 15 min

Identification of *Francisella tularensis* genes necessary for the induction of prostaglandin E2 from infected macrophages
Matthew Woolard, Louisiana State University Health Science Center (USA) 15 min

Defining the correlates of protective immunity to type A *Francisella tularensis*
Jason Huntley, UT Southwestern Medical Center (USA) 15 min

The 58-kDa major virulence factor, FTT0918, of *Francisella tularensis* is required for utilization of iron
Helena Lindgren, Umeå University (Sweden) 15 min

Sunday, 13 Sep

Monday, 14 Sep

Tuesday, 15 Sep

Wednesday, 16 Sep

Sunday, 13 Sep

Monday, 14 Sep

Tuesday, 15 Sep

Wednesday, 16 Sep

13.30 – 15.00 h

AUDITORIUM

S 9 – Cell Biology

Chairs: Jean Celli, NIAID / National Institutes of Health (USA)
Lee-Ann Allen, University of Iowa (USA)

Intracellular transcriptional profiling of *Francisella* reveals novel determinants of intracellular proliferation

Jean Celli, NIAID / National Institutes of Health (USA)

25 min

Protein kinase C signaling and global disruption of macrophage membrane trafficking by *Francisella tularensis*

Lee-Ann Allen, University of Iowa (USA)

25 min

Integrating *Francisella*'s intracellular lifestyle

Simon Daefler, Mount Sinai School of Medicine (USA)

20 min

Mast cell-mediated signaling in reduction of *Francisella tularensis* SchuS4 intramacrophage replication and apoptosis

Annette Rodriguez, University of Texas at San Antonio (USA)

20 min

15.30 – 17.20 h

AUDITORIUM

S 10 – Responses of Host Cells to *Francisella*

Chairs: Marina Santic, University of Rijeka (Croatia)
Susheela Tridandapani, Ohio State University (USA)

Modulation of the host cell biology by *Francisella tularensis*

Marina Santic, University of Rijeka (Croatia)

25 min

Genome-wide analysis of human monocytes infected with *F. tularensis* identifies new targets of host response subversion

Susheela Tridandapani, Ohio State University (USA)

25 min

Primary human alveolar type II epithelial (ATII) cells modulate human macrophage responses to *Francisella tularensis* Schu 4

Tonyia Eaves-Pyles, University of Texas at San Antonio (USA)

20 min

Erythrocyte invasion by *Francisella tularensis*

Gerard Nau, University of Pittsburgh School of Medicine (USA)

20 min

Quantitative proteomic profiling of host – pathogen interaction: The interaction of *Francisella tularensis* LVS with macrophages using J774.2 cell line

Anetta Hartlova, University of Defence (Czech Republic)

20 min

TIME	AUDITORIUM	FOYER
09.00 – 10.00 h	S11 – Status of Non-Human Primate Models of <i>Francisella</i> Infection	
09.55 – 10.15 h		Coffee
10.15 – 12.05 h	S12 – Mechanisms of Immunity, Vaccination and Immunotherapy	
12.05 – 12.15 h	Closing Remarks	
12.15 – 13.00 h	Meeting of the Tularemia International Society	
from 13.00 h	Social-scientific event Visit of the Robert Koch Memorial Bus-Sight-seeing tour Berlin	

09.00 – 10.00 h AUDITORIUM

S 11 – Status of Non-Human Primate Models of *Francisella* Infection

Chairs: Rick Lyons, University of New Mexico (USA)
Jiri Stulik, University of Defence (Czech Republic)

Humoral immunity to *Francisella tularensis* strain LVS fails to uniformly protect Cynomolgus macaques from disease induced by aerosol infection with strain SchuS4
Julie Wilder, Lovelace Respiratory Research Institute (USA) 20 min

Exposure of cynomolgus macaques to aerosolized *Francisella tularensis* SchuS4
H. Carl Gelhaus, Battelle Biomedical Research Center (USA) 15 min

Comparison of aerosolized *F. tularensis* in three species of nonhuman primates
Aysegul Nalca, USAMRIID (USA) 10 min

Discussion of status of NHP models 10 min

10.15 – 12.05 h AUDITORIUM

S 12 – Mechanisms of Immunity, Vaccination and Immunotherapy

Chairs: Wayne Conlan, National Research Council Canada (Canada)
Dennis Metzger, Albany Medical College (USA)

Novel live vaccine candidates against airborne *Francisella tularensis*
Wayne Conlan, National Research Council Canada (Canada) 25 min

Type A *F. tularensis* induces caspase-3-dependent macrophage death in infected tissues
Michael Parmely, University of Kansas Medical Center (USA) 20 min

Molecular Mechanisms Responsible for Antibody-Mediated Clearance of *F. tularensis*
Dennis Metzger, Albany Medical College (USA) 25 min

Essential elements of protective immunity to *Francisella*
Karen Elkins, CBER / FDA (USA) 20 min

Derivation of a panel of potential correlates of vaccine-induced protection against *Francisella tularensis* LVS
Roberto De Pascalis, CBER / FDA (USA) 20 min

12.05 – 12.15 h AUDITORIUM

Closing Remarks

12.15 – 13.00 h AUDITORIUM

First Meeting of the Tularemia International Society

The Organizers gratefully acknowledge the support of the following associations and companies.

ROBERT KOCH INSTITUT



Robert Koch-Institute, Germany



Defence Science and Technology Laboratory, UK



National Institutes of Health

National Institutes of Health, USA



National Institute of Allergy and Infectious Diseases, USA

Congress Location

University Hospital Charité
Charité Campus Mitte (CCM)
Charitéplatz 1
10117 Berlin, Germany

Registration Counter

The registration desk in the entrance hall of the CCM will be open as follows:

Opening Hours

Sunday,	13 Sep	09.00 – 20.00 h
Monday,	14 Sep	08.00 – 19.00 h
Tuesday,	15 Sep	08.30 – 17.30 h
Wednesday,	16 Sep	08.30 – 13.00 h

Registration Fees

Registration fee for participants includes:

- Admission to Scientific Sessions
- Congress Bag with numerous Congress Documents
- Abstract CD
- Lunch, Tea and Coffee Breaks
- Get Together on Sunday, 13 September 2009 and Monday, 14 September 2009
- Gala Dinner at TV Tower on Tuesday, 15 September 2009 (registration required)

Media Check

The Auditorium is equipped with computer projection. Speakers are asked to hand in their presentations at least two hours before their speech in the media check (Conference A). Speakers having a presentation during the first time slot in the morning are asked to hand in their slides the day before.

Opening Hours

Sunday,	13 Sep	09.00 – 20.00 h
Monday,	14 Sep	08.00 – 19.00 h
Tuesday,	15 Sep	08.30 – 17.30 h
Wednesday,	16 Sep	08.30 – 13.00 h

Congress Language

The congress language is English.

Poster Exhibition

- Scientific Posters will be displayed in the foyer of the Auditorium.
- The size of your poster should not exceed 100 cm width and 130 cm height.
- The posters of session P1 should be set-up on Sunday, 13 September 2009, between 09.00 h and 10.00 h. Those should be removed until Monday, 14 September 2009, 09.00 h.
- The posters of session P2 should be set-up on Monday, 14 September 2009, between 12.15 h and 13.30 h. Those should be removed until Tuesday, 15 September 2009, 09.00 h.

A poster information desk will be located next to the registration desk. Lists indicating title, author and poster number will be displayed at the desk. Material for fixing the poster will be provided by the staff of the poster help desk. The poster desk staff will be on your disposal to answer your questions and provide help locating the poster on site.

- Please do not use your own adherence materials! In case of negligence, claims for compensation may be raised.

Poster Award

The Poster Prize is generously supported by the National Institute of Health, USA and will be awarded at the Gala Dinner at TV Tower on Tuesday, 15 September 2009.

Cloakroom

The cloakroom is centrally located on the entrance level across the registration desk.

Coffee Breaks /Lunch

The coffee breaks and lunches are included in the registration fee. *They will be served on the entrance foyer and foyer of the Auditorium.*

Certificate of Attendance

All participants receive a certificate of attendance.

BERLIN INFORMATION

Berlin, the Capital of Germany, is located at the heart of Europe and also, after EU enlargement in 2004, at the centre of the European Community. With more than 3 million inhabitants, Berlin is the largest city in Germany.

History has left an unforgettable mark on Berlin. It is not only the city's memorials which evoke images of its unique, turbulent history. Nearly 20 years after the fall of the Berlin Wall, the city never ceases to change and develop.

With about 170 museums and more than 300 galleries the capital boasts a highly impressive range of unique, internationally renowned collections. More than 150 theatres, 3 first-class opera houses, 8 major symphony orchestras, 2 major musical theatres, variety theatres as well as countless cabarets provide entertainment to suit every possible taste.

Discovering Berlin will be a memorable experience for all congress delegates. The city and its charming surroundings, with its famous places of cultural and historical interest, offer a unique range of cultural and recreational attractions.

Climate

Germany has a temperate climate. The average temperature in September for Berlin is 15°C/45°F.

Credit Cards

EC cards and credit cards (American Express, Visa, Diners Club, Eurocard, Mastercard) are accepted virtually everywhere.

Currency

1 euro = 100 cents

Coins: 1, 2, 5, 10, 20, 50 Cents; 1, 2 euros

Bills: 5, 10, 20, 50, 100, 200, 500 euros

Cash can be obtained around the clock from cash points with EC cards and all common international credit cards.

Electricity

Electricity in Germany is supplied at 220 V – 50 Hz.

Insurance

Delegates are advised to take out their own medical, travel and accident insurance. The organizers cannot accept responsibility for personal injuries, loss or damage to private property belonging to delegates and/or accompanying

Time

Germany is on Central European Time (CET) and is one hour ahead of Greenwich Mean Time, 6 hours ahead of Eastern Standard Time and 9 hours ahead of Pacific Standard Time. Summer Time extends from the last Sunday in March to the last Sunday in October.

Tipping

Although all prices officially include a service charge, tipping is recommended – as long as you are satisfied: Taxi: 10%, Restaurant: 10–15%, Porter (hotel): € 2–3 depending on the standard of the hotel, Chambermaid: € 2–3 depending on the standard of the hotel, Hairdresser: 10%.

SUPPORTING PROGRAM

Through Berlin's Past, Present and Future in the Fast Lane

This bus tour (approx. 3 hrs.) covers the sights and famous memorial sites, as well as the contradictions and contrasting sides of Berlin. You'll get off the bus and into the scene of things at a number of places to learn more about the city's many facets. You are guided to the historic city center, to both the former and current East and West Berlin, across Potsdamer Platz, to government sites old and new, across Stalinist boulevards and modern avenues.

Wednesday, 16 September 2009, 13.30 h

Price: 35 € incl. VAT

as per 2nd September 2009.

Further contact details can be provided by the Chairman of the Local Organizing Committee on request.

LAST NAME	FIRST NAME	INSTITUTE	COUNTRY
Abu Kwaik	Yousef		USA
Akimana	Christine	University of Louisville	USA
Al Khodor	Souhaila	University of Louisville	USA
Allen	Lee-Ann	University of Iowa	USA
Anda	Pedro	Instituto de Salud Carlos III	Spain
Anderson	Rebecca		USA
Ariel	Naomi	Israel Institute for Biological Research	Israel
Ark	Nicole	University of Virginia Health System	USA
Arulanandam	Bernard	University of Texas at San Antonio	USA
Bäck	Erik	Örebro University Hospital	Sweden
Bakanidze	Lela	National Center for Disease Control	Georgia
Bakshi	Chandra Shekhar	Albany Medical College	USA
Balonova	Lucie	University of Defence, Faculty of Military Health Sciences	Czech Republic
Barduhn	Anne	Robert Koch-Institute	Germany
Barel	Monique	INSERM	France
Bar-Haim	Erez		Israel
Barker	Jeffrey	University of Texas at San Antonio	USA
Barry	Eileen	Bechtel National Inc	USA
Becker	Silke	Robert Koch-Institute	Germany
Belisle	John	Colorado State University	USA
Benach	Jorge		USA
Bosio	Catharine	Rocky Mountain Laboratories	USA
Boskani	Talar	Swedish Institute for Infectious Disease Control	Sweden
Braunstein	Gavin	Defense Threat Reduction Agency	USA
Bröms	Jeanette	Umea University	Sweden
Bublitz	DeAnna		USA
Busse	Hans-Juergen	Veterinary University Vienna	Austria
Celli	Jean	Rocky Mountain Laboratories, NIAID, NIH	USA
Cervený	Lukas	University of Defence	Czech Republic

LAST NAME	FIRST NAME	INSTITUTE	COUNTRY
Chambers	Jacob	Southern Illinois University – Carbondale	USA
Chambers	James	University of Texas at San Antonio	USA
Champion	Anna	Virginia Polytechnic and State University	USA
Charbit	Alain	INSERM	France
Charity	James	Harvard Medical School	USA
Chou	Alicia	FDA / CBER	USA
Chu	May	World Health Organization	Switzerland
Cohen	Ofer	IIBR	Israel
Cong	Yu	University of Texas at San Antonio	USA
Conlan	Wayne	National Research Council Canada	Canada
Cowley	Siobhan	FDA	USA
Cremer	Thomas	DHLRI 465	USA
DaSilva	Luis	USAMRIID	USA
de Pascalis	Roberto	Laboratory of Mycobacterial Disease	USA
DeBord	Kristin	National Institute of Health	USA
Dorman	William	USAMRIID	USA
Dove	Simon	Children's Hospital	USA
Drevinek	Michal	Natl. Institute for NBC Protection	Czech Republic
DuBois	Amanda	University of New Mexico	USA
Duodu	Sameul	National Veterinary Institute	Norway
Dupke	Susann	Robert Koch-Institute	Germany
Dürrenfeld	Adina	Robert Koch-Institute	Germany
Eaves-Pyles	Tonyia	University of Texas Medical Branch	USA
Edvinsson	Benjamin	Swedish Institute for Infectious Disease Control	Sweden
Elkins	Karen	Center for Biologics Evaluation and Research / U.S. FDA	USA
Eneslätt	Kjell	Umea University	Sweden
Escudero	Raquel	CNM-Instituto de Salud Carlos III	Spain
Fabbi	Massimo	Istituto Zooprofilattico Sperimentale della Lombardia	Italy
Farhadi	Linn	Swedish Institute for Infectious Disease Control	Sweden
Fisher	David	Battelle Memorial Institute	USA
Fisher	Nathan	USAMRIID	USA
Forsberg	Ake	Umea University	Sweden

LAST NAME	FIRST NAME	INSTITUTE	COUNTRY
Forslund	Anna-Lena	Umeå University	Sweden
Forsman	Mats	Swedish Defence Research Institute	Sweden
Frelinger	Jeffrey	University of North Carolina	USA
Fucikova	Alena	Faculty of Pharmacy in Hradec Kralove	Czech Republic
Furie	Marta		USA
Gavrilin	Mikhail	The Ohio State University	USA
Geier	Henriette	Rocky Mountain Laboratories	USA
Gelhaus	Carl	Battelle Biomedical Research Center	USA
Georgi	Enrico	Bundeswehr Institute of Microbiology	Germany
Golovliov	Igor	Umea University	Sweden
Griffith	Barbara	University of Mexico	USA
Grosfeld	Haim	Israel Institute for Biol. Res.	Israel
Grunow	Roland	Robert Koch-Institute	Germany
Guentzel	M.Neal	University of Texas	USA
Gulati	Sunita	University of Massachusetts	USA
Guttman	Julian	Simon Fraser University	Canada
Gvantsa	Chanturia	National Center for Disease Control	Georgia
Gyuranecz	Miklos	Szent Istvan University	Hungary
Hacker	Jörg	Robert Koch-Institute	Germany
Hare-Sanford	Rebekah	University Alaska Fairbanks	USA
Härtlova	Anetta	University of Defence, Faculty of Military Health Sciences	Czech Republic
Hawkey	Suzanna	Health Protection Agency	United Kingdom
Hazlett	Karsten	Albany Medical College	USA
Hernychova	Lenka	Faculty of Military Health Sciences	Czech Republic
Hofer	Erwin	Institute for Veterinary Disease Control, Mödling, Ages	Austria
Horwitz	Marcus	University of California – Los Angeles	USA
Howaldt	Sabine	Robert Koch-Institute	Germany
Hubalek	Martin	Institute of Molecular Pathology, FMHS UD	Czech Republic
Hueffer	Karsten	University of Alaska	USA
Huntley	Jason	University of Texas Southwestern Medical Center	USA
Hutt	Julie	Lovelace Respiratory Research Institute	USA
Inzana	Thomas	Virginia Tech	USA

LAST NAME	FIRST NAME	INSTITUTE	COUNTRY
Jacob	Daniela	Robert Koch-Institute	Germany
Jia	Qingmei	School of Medicine, University of California, Los Angeles	USA
Johansson	Anders	Umeå University	Sweden
Jones	Brad	The University of Iowa	USA
Jones	Crystal	Emory University	USA
Jones	Jonathan	Stanford University	USA
Kadzhaev	Konstantin	Umea University	Sweden
Karadenizli	Aynur		Turkey
Kawula	Tom	University of North Carolina	USA
Keim	Paul		USA
Kießling	Sonja	Robert Koch-Institute	Germany
Kijek	Todd	University of North Carolina, Chapel Hill	USA
Klein	Iris	Robert Koch-Institute	Germany
Klimentova	Jana	Faculty of Military Health Sciences, University of Defence	Czech Republic
Klimpel	Gary	University Texas Medical Branch at Galveston	USA
Klose	Karl	UTSA	USA
Knauer	Nadine	Institut für Mikrobiologie der BW	Germany
Krocova	Zuzana	Faculty of Military Health Sciences	Czech Republic
Kubelkova	Klara	University of Defence, Faculty of Military Health Sciences	Czech Republic
Kühn	Andrea	Robert Koch-Institute	Germany
Kuoppa	Kerstin	FOI – Swedish Defence Research Agency	Sweden
Latham	Jennie	Health Protection Agency	United Kingdom
Lavander	Moa	Umea University	Sweden
Le Pihive	Emmanuelle	Institut de Recherches Biomédicales des Armées	France
Lindgren	Helena	Umea University	Sweden
Lindgren	Lena	Umea University	Sweden
Lindgren	Marie	Umea University	Sweden
Lipscomb	Mary	University of New Mexico HSC	USA
Llewellyn	Anna	Emory University	USA
Lochau	Petra	Robert Koch-Institute	Germany
Löfström	Emma		Sweden

LAST NAME	FIRST NAME	INSTITUTE	COUNTRY
Lopes de Carvalho	Isabel	CEVDI/INSA	Portugal
Lyons	Rick	University of New Mexico HSC	USA
Macela	Ales	University of Defense	Czech Republic
Madani	Nora	AFSSA	France
Mann	Barbara	University of Virginia	USA
Manoil	Colin	University of Washington	USA
Mara Koosham	Gopi	University of New Mexico	USA
Margolis	Jeffrey	Stanford University	USA
Mathisen	Peter	Umea University	Sweden
McCaig	William		USA
McNealy	Tamara	Clemson University	USA
Meibom	Karin	INSERM	France
Meierovics	Anda	Center for Biologies Evaluation and Research	USA
Meister	Beate	Robert Koch-Institute	Germany
Melendez	J. Andres	Albany Medical College	USA
Melillo	Amanda	Albany Medical College	USA
Metreveli	Magda	Bechtel National Inc	Georgia
Metzger	Dennis	Albany Medical College, MC-151	USA
Miller	Cheryl	University of North Carolina Chapel Hill	USA
Möhlig	Heike	Institut Vivion / Sevion GmbH	Germany
Molins Schneekloth	Claudia	Centers for Disease Control and Prevention	USA
Mortensen	Brittany	University of North Carolina-Chapel Hill	USA
Nalca	Aysegul	USAMRIID	USA
Nano	Francis	University of Victoria	Canada
Nattermann	Herbert	Robert Koch-Institute	Germany
Nau	Gerard	University of Pittsburgh School of Medicine	USA
Noh	Susan	Animal Disease Research Unit	USA
Noppa	Laila	FOI Swedish Defence Research Agency	Sweden
Núncio Soares	Maria Sofia	Instituto Nacional de Saude Dr. Ricardo Jorge	Portugal
Obiso	Richard	Bechtel National Inc	USA
Oyston	Petra	DSTL	United Kingdom
Parmely	Michael	University of Kansas Medical Center	USA

LAST NAME	FIRST NAME	INSTITUTE	COUNTRY
Pascucci	Ilaria	Istituto 200 Profilattico del Molise „G. Caporale“	Italy
Pavkova	Ivona	Faculty of Military Health Sciences, University of Defence	Czech Republic
Pearson	Andrew	Health Protection Agency	United Kingdom
Petersen	Jeannine	Centers for Disease Control and Prevention	USA
Peterzon	Anna	Swedish Institute for Infectious Disease Control	Sweden
Pilo	Paola	Institute for Veterinary Bacteriology	Switzerland
Prior	Joann	DSTL	United Kingdom
Qin	Aiping	University of Virginia	USA
Ramakrishan	Girija		USA
Ray	Heather	University of Texas at San Antonio	USA
Raymond	Claudine	National Research Council of Canada	Canada
Reese	Sara	Centers for Disease Control	USA
Reisp	Katharina	Austrian Agency for Health and Food Safety	Austria
Rietz	Anna Cecilia J	Lovelace Respiratory Research Institute	USA
Roberts	Samantha	FDA/CBER	USA
Rodriguez	Annette	University of Texas at San Antonio	USA
Rodriguez Gay	Carolina	Sanofi Pasteur MSD	Spain
Rohleder	Anna	Robert Koch-Institute	Germany
Runge	Martin	LAVES – Veterinary Institute Hannover	Germany
Saint	Richard	DSTL Porton Down	United Kingdom
Salomonsson	Emelie	FOI – Swedish Defence Research Agency	Sweden
Sammons-Jackson	Wendy	USAMRIID	USA
Santic	Marina	Medical Faculty	Croatia
Sauer	Uschi	Robert Koch-Institute	Germany
Schaefer	Michael	National Institutes of Health	USA
Schmiedl	Andreas	Institut Vivion / Sevion GmbH	Germany
Schmitt	Deanna	University of Pittsburgh	USA
Schmoldt	Sabine	Institut für Mikrobiologie der Bundeswehr	Germany
Schürch	Nadia	Spiez Laboratory	Switzerland
Schwartz	Justin	University of Iowa	USA
Seibold-Krämer	Erik	Bundeswehr Institute for Microbiology	Germany

LAST NAME	FIRST NAME	INSTITUTE	COUNTRY
Shahjahan	Shaid	Robert Koch-Institute	Germany
Shavishvili	Merab	National Center for Disease Control	Georgia
Shea	April	USAMRIID/Akimeka Technologies, LLC	USA
Sherwood	Robert	Lovelace Respiratory Research Institute	USA
Sheshko	Valeria	University of Defence, Faculty of Military Health Sciences	Czech Republic
Signarovitz	Aimee	University of Texas at San Antonio	USA
Simsek	Hülya	Refik Saydam National Public Health Agency	Turkey
Sjöstedt	Anders	Umea University	Sweden
Smith	Stephanie	Battelle Memorial Institute	USA
Sperandio	Vanessa	UT Southwestern Medical Center	USA
Spidlova	Petra	Faculty of Military Health Sciences	Czech Republic
Spletstoesser	Wolf D.	Bundeswehr Institute of Microbiology	Germany
Stöven	Svenja	Umea University	Sweden
Straskova	Adela	University of Defence, Faculty of Military Health Sciences	Czech Republic
Stulik	Siri	Faculty of Military Health Sciences, University of Defence	Czech Republic
Svensson	Kerstin	Swedish Defence Research Agency (FOI)	Sweden
Taft-Benz	Sharon	University of North Carolina	USA
Taner	Müge	Refik Saydam National Public Health Agency	Turkey
Telford	Sam	Tufts University	USA
Thanassi	David		USA
Thomas	Rebecca	DSTL	United Kingdom
Tomaso	Herbert	Friedrich-Löffler-Institut	Germany
Tridandapani	Susheela	The Ohio State University	USA
Valade	Eric	IRBA / CRSSA	France
Valderas	Michelle	Lovelace Respiratory	USA
Van Zandt	Kristopher	Battelle Memorial Institute	USA
Vicari	Nadia	Istituto Zooprofilattico della Lombardia ed Emilia Romagna	Italy
Volkmar	Sven	Robert Koch-Institute	Germany
Vyrostekova	Vanda	Comenius University, Medical Faculty	Slovakia
Wahab	Tara	Swedish Institute for Infectious Disease Control	Sweden

LAST NAME	FIRST NAME	INSTITUTE	COUNTRY
Weber	Martin	Institut für Mikrobiologie der Bundeswehr	Germany
Weiss	David	Emory University	USA
Wilder	Julie	Lovelace Respiratory Research Institute	USA
Winther-Larsen	Hanne C.	Norwegian School of Veterinary Sciences	Norway
Wittwer	Matthias	Spiez Laboratory	Switzerland
Wolcott	Mark	USAMRIID	USA
Wolfram	Lawrence	Dynport Vaccine CO, LLC CSC	USA
Woolard	Matthew	Louisiana State University Health Science Center at Shrevepo	USA
Xu	Zuoyu	National Institutes of Health	USA
Yu	Jieh-Juen	University of Texas at San Antonio	USA
Zaide	Galia		Israel
Zheng	Huaixin		USA
Zingmark	Carl	Umea University	Sweden
Zivna	Lucie	Faculty of Military Health Sciences	Czech Republic
Zou	Lanling	National Institutes of Health	USA

Abu Kwaik, Y. P1-33, P2-50, S 10-1
 Agarwal, S. P2-63
 Åhlund, M. P2-32
 Akimana, C. P1-33, P2-50
 Al Khodor, S. P2-50
 Allen, L.-A.H. P2-27, P2-56
 Allroy, J. P2-37
 Allue, M. S 7-1
 Alves, D. S 11-3
 Amer, A. P2-33
 Anda, P. S 4-3
 Anderson, R.V. P2-22
 Andersson, A.-C. P2-06
 Apicella, M. S 1-4
 Ark, N.M. P1-28
 Arulanandam, B. P2-61
 Arulanandam, B.P. P2-23, P2-40, P2-62,
 S 4-5, S 9-4
 Asare, R. P1-33
 Atkins, H. P2-30
 Auerbach, R. K. S 5-1
 Bäck, E. S 7-3
 Bäckman, S. P2-06
 Bakanidze, L. P1-04
 Bakshi, C.S. P1-26, P2-35
 Balonova, L. P1-12
 Balu, S. P2-48
 Bandara, A. S 1-4
 Barel, M. P1-13, S 8-1
 Bar-Haim, E. P1-11, P2-46
 Barker, J.R. P1-16
 Barnewall, R. P2-65, S 11-2
 Barnewall, R.E. P2-52, P2-53
 Barr, E. P2-29, P2-49
 Bastian, M. S 8-2
 Battles, K. P2-53, S 11-2

Becker, S. P1-43, P1-45
 Beckstrom-Sternberg, J.S. S 5-1
 Beckstrom-Sternberg, S. S 5-1
 Belisle, J. P2-22
 Belisle, J.T. P2-60
 Benach, J.L. P2-24
 Benada, O. P1-32
 Bender, K.S. P1-06
 Berg, G. P2-37, P2-55
 Berhe, F. P2-31
 Berton, M.T. S 9-4
 Bestek, S. P2-16
 Bilkova, Z. P1-12
 Birdsell, D. S 5-1
 Björk, R. S 7-2
 Blalock, L.T. P1-23
 Blau, D. P2-57
 Bokhari, S.M. S 12-2
 Bosio, C.M. P2-22
 Bowers, J. S 5-1
 Brasel, T. P2-29, P2-49, S 11-1
 Brasel, T.L. P2-26
 Braune, S. P1-46
 Brayton, K.A. P1-03
 Brettin, T. S 5-3
 Bryant, C. P2-30
 Bublitz, D.C. P2-24
 Buchhagen, J. S 5-1
 Burton, J. P1-14
 Busse, H.-J. S 4-4
 Butchar, J.P. P2-33, S 10-2
 Cao, W. P2-11
 Carlson Jr., P.E. P2-59
 Castrodeza, J. S 7-1
 Cavallo, J.-D. P1-34
 Celli, J. P2-34

Cervený, L. P1-30
 Chain, P. P1-04
 Chambers, J.P. P2-62, S 4-5, S 9-4
 Chambers, J.R. P1-06
 Champion, A. S 1-4
 Chanturia, G. P1-04
 Charbit, A. P1-13, S 2-1, S 8-1, S 10-1
 Charity, J.C. P1-23
 Chase, J. P2-22
 Chiavolini, D. P2-37
 Chou, A.Y. P2-45, S 12-5
 Christian, K. P2-37
 Chu, M. P1-35
 Chu, P. P2-40, P2-61
 Clare, A. S 5-1
 Clay, C.D. P2-33, S 10-2
 Cohen, H. P2-46
 Cohen, M. S 6-2
 Cohen, O. P1-11
 Colquhoun, D. P2-17
 Cong, Y. P2-23, P2-61
 Conlan, J.W. P2-54, S 12-1
 Conlan, W. S 8-5
 Costante-Hamm, M. P1-23
 Cowley, S.C. P2-42
 Crane, D. P2-22
 Cremer, T.J. P2-33, S 10-2
 Cross, J. S 11-2
 Cross, J.M. P2-53
 Daefler, S. P1-01
 DaSilva, L. P2-57
 De Pascalis, R. S 12-5
 Delorey, M.J. P2-60
 Dempsey, M.P. S 5-1
 Dietrich, G. P2-03
 Djordjevic, M.M. P1-39

Dolan, M.C. P2-03
 Dorman, W. P1-16
 Dove, S.L. P1-23, S 3-2
 Downey, T. P2-57
 Dresler, J. P1-07
 Duan, Q. P2-11
 DuBois, A.B. P2-25
 Duerrenfeld, A. P2-08
 Duodu, S. P2-17
 Durand, B. P1-40
 Eaves-Pyles, T. S 10-3
 Edvinsson, B. P1-37
 Ehrlich, S. P1-11
 Eisen, R.J. P2-03
 El Khoury, M. P1-40
 El-Etr, S. P2-01, S 6-2
 Elfsmark, D. S 5-3
 Elía, M. S 4-3
 Eliasson, H. S 7-3
 Elkins, K.L. P2-42, P2-43, P2-45,
 S 12-4, S 12-5
 Elliott, J. P1-04
 Elton, T.S. P2-33
 Engelthaler, D.M. S 5-1
 Enstrom, M. S 3-4
 Ertek, M. S 4-2
 Erwin-Cohen, R. P2-57, S 11-3
 Escudero, R. S 4-3
 Espenshade, O. S 11-3
 Fabbi, M. P2-10
 Falck, J.R. S 6-1
 Fischer, J.L. S 12-2
 Fisher, D. P2-51, P2-65
 Fisher, N. P1-25
 Forsberg, Å. P2-47, S 2-4, S 4-1
 Forslund, A.-L. P2-47, S 2-4

Forsman, M. P1-29, P1-35, P2-06,
P2-21, S 5-3, S 7-2

Foxall, P. S 5-1

Frangoulidis, D. S 8-2

Frelinger, J.A. P2-28, S 8-3

Frelinger, J.G. P2-28

Friedlander, A. P1-25

Friedman, G. P1-11

Fuller, J. P1-22, S 1-3

Furie, M.B. P1-19, P2-24

Gaciková, E. P2-15

Galán, J.A. S 4-3

Gallagher, L. P1-21

Gallardo, M.T. S 7-1

Garcia, E. P1-04

Garin-Bastuji, B. P1-40

Gat, O. P1-11, P2-46

Gavrilin, M.A. P2-31, S 10-2

Geier, H. P2-34

Gelhaus, H.C. P2-51, S 11-2

Georgi, E. P1-17, P1-41

Gil, H. S 4-3

Glynn, A. S 11-3

Goethert, H.K. S 7-4

Golovlev, I. S 8-5

Golovliov, I. P2-47, S 2-4, S 12-1

Grall, N. P1-13

Granberg, M. P2-21

Grauer, A. P1-46

Grunow, R. P1-35, P1-36, P1-37, P1-42,
P1-43, P1-45, P2-08, P2-14, P2-16

Guentzel, M.N. P2-23, P2-40, P2-62,
S 4-5, S 9-4

Guglielmo-Viret, V. P1-44

Gulati, S. P2-63, P2-64

Gunn, J.S. P1-18, P2-33

Guryčová, D. P2-13, P2-15

Hare-Sanford, R.F. P1-27

Harrison, R. P2-64

Hartlova, A. S 10-5

He, J. P2-11

Hedenström, I. P2-09

Heffron, F. P1-21

Held, K. S 3-4

Heller, E. P2-65

Hensley, L. P2-28

Hernychova, L. P1-09, P1-12, P1-32

Herrera, L. S 4-3

Hjertqvist, M. P2-09

Hofer, E. P2-05

Holz, C. S 4-1

Honn, M. S 8-5

Horvat, R.T. S 12-2

Horwitz, M.A. P2-36

Horzempa, J. P2-59, S 10-4

House, R.V. S 12-1

Huang, M. S 1-3

Hubalek, M. P1-31

Huber, B. S 4-4

Hueffer, K. P1-27

Huntley, J. S 6-1

Huntley, J.F. S 8-4

Hutt, J. P2-29

Hutt, J.A. P2-25, P2-26, P2-44

Hying, J. S 11-2

Hying, J.V. P2-53

Imnadze, P. P1-04

Ingle, C. S 8-4

Inzana, T. S 1-4

Inzana, T.J. P2-55

Ireland, R. P2-22

Ivanyi, J. P2-48

Jacob, D. P1-36, P1-37, P1-43, P1-45

Jado, I. S 4-3

Jedlickova, V. P1-31

Jia, Q. P2-36

Johansson, A. P1-35, P2-21, S 5-1,
S 5-3, S 7-2

Jones, J. S 2-3

Joubert, L.-M. P2-01

Jurcic-Momcilovic, D. S 10-1

Kadzhaev, K. S 8-5

Kalaveshi, A. P2-14

Kämpfer, P. S 4-4

Kanneganti, T.-D. P2-33

Karadenizli, A. S 4-2

Karlsson, L. P2-21

Kasper, D.L. P1-23

Kawula, T. P1-22, P2-28, S 1-3

Kawula, T.H. S 8-3

Keim, P. S 5-3

Keim, P.S. S 5-1

Kekelidze, M. P1-04

Kijek, T. P1-22, S 1-3

Kirtley, M. S 10-3

Klement, C. P2-13

Klimentova, J. P1-07

Klose, K.E. P1-16, P2-23, P2-40, P2-61,
P2-62, S 4-5, S 9-4

Knauer, N. S 8-2

Koczan, D. S 8-2

Konecna, K. P1-32

Koomey, M. S 4-1

Kostic, V. P1-39

Kouppa, K. P2-06

Krile, R. P2-51, P2-53, P2-65, S 11-2

Kroca, M. P1-30

Krocova, Z. P2-41

Krstic, M. P1-39

Krüger, R. P1-45

Kubelkova, K. P2-48

Kubota, K. S 5-2

Kuehn, A. P2-14, P2-16

Kugeler, K. S 5-2

Kühn, A. P1-43

Kuoppa, K. P2-47, S 2-4

Kutzer, P. P1-43, P2-16

Lai, X.-H. P1-21

Lair, A. P1-18

Lako, B. P1-39

Lao, V.H.I. P1-04

Larsson, P. P1-29, S 5-3

Latham, J. P1-14

Laue, M. P2-08

Lauriano, C. P2-61

Lee, B.-Y. P2-36

Lee, D. S 6-1

Lenco, J. S 10-5

Lindblom, A. S 7-2

Lindgren, H. S 8-5

Lindsay, A. P2-65, S 11-2

Lindsay, A.S. P2-53

Link, M. P1-10, S 10-5

Liu, W. P2-11

Livny, J. P1-13

Llewellyn, A. S 1-2

Llewellyn, A.C. P1-15

Lochau, P. P1-43

Lockman, H.A. P2-51, P2-53, S 11-2

Löfdahl, S. P2-09

Löfström, E. S 7-3

Long, L. P1-25

Lopes de Carvalho, I. P2-12

Luebbert, C. P1-42

Lundström, J. P2-06, S 7-2
 Lyons, C.R. P2-25, P2-26, P2-29,
 P2-44, S 11-1
 Mad'arová, L. P2-13
 Maben, Z. P2-28
 Macela, A. P1-31, P2-48
 Madani, N. P1-40
 Madela, K. P2-08
 Madico, G. P2-63
 Madico, G.E. P2-64
 Mahajan, U. S 6-3
 Mahawar, M. P1-26
 Maier, B. S 4-1
 Mann, B.J. P1-20, P1-28, S 1-1
 Manoil, C. P1-03, P1-21, S 3-4, S 8-3
 Mara Koosham, G. P2-44
 Margolis, J.J. P2-01, S 6-2
 Marino Merlo, L. P2-10
 Markel, G. P2-46
 Marsh, C.B. P2-33
 Mason, J. P1-14
 Mateos, L. S 7-1
 Mathisen, P. P2-06
 Maylaender, N. P1-17
 McCaig, W.D. P1-08
 McNealy, T.L. S 6-3
 McPherson, P. P2-28
 Mead, P.S. S 5-2
 Meeker, A. P1-24
 Meibom, K. S 10-1, S 8-1
 Meibom, K.L. P1-13
 Meierovics, A.I. P2-42
 Melendez, A.J. P1-26
 Melendez, J.A. P2-35
 Melillo, A. P2-35
 Melillo, A.M. P1-26

Mendelson, I. P1-11
 Mendenhall, A. P2-57
 Mendy, C. P1-40
 Menéndez, V. S 4-3
 Mérens, A. P1-34
 Messeri, D. P2-10
 Metzger, D.W. P1-26, S 12-3
 Michell, S. S 2-4
 Michell, S.L. P1-05
 Miller, C. S 1-3
 Mitra, S. P2-31
 Molins, C. S 5-2
 Molins, C.R. P2-60
 Monack, D. S 2-3, S 6-2
 Monack, D.M. P2-01
 Monier, A. S 11-1
 Moore, E. P2-01, S 6-2
 Moore, K. P1-18
 Moreira, C. S 6-1
 Mortensen, B. P1-22, S 1-3
 Müller, W. P1-46
 Mulliqi Osmani, G. P2-14
 Munerman, P. P1-25
 Murthy, A.K. P2-62
 Nalca, A. S 11-3
 Nallaparaju, K. P2-62
 Nano, F. S 2-2
 Napier, B. S 1-2
 Nattermann, H.R. P1-43, P1-45, P2-16
 Nau, G.J. P2-59, S 10-4
 Neubauerova, V. P2-21
 Noh, S.M. P1-03
 Noppa, L. P2-47, S 2-4
 Norgard, M.V. S 8-4
 Novotny, M.V. P1-12
 Nowak, N. P2-63

Núncio, M.S. P2-12
 O' Dee, D.M. P2-59
 O'Dee, D. S 10-4
 Otto, P. P1-46
 Oyston, P. S 2-4
 Oyston, P.C. P1-05
 Oyston, P.C.F. S 3-3, S 12-1
 Pak, D. P2-53, P2-65, S 11-2
 Palmer, G.H. P1-03
 Palmer, L.E. P1-19
 Paranavitana, C. P2-57
 Parmely, M.J. S 12-2
 Pavkova, I. P1-10
 Pavokovic, G. S 10-1
 Pearson, A. P1-14
 Pearson, A.D. P2-07, P2-18, P2-19, P2-20
 Pearson, K. P1-14
 Pearson, T. S 5-1
 Pejchal, J. P1-31
 Perelli, G. P2-10
 Perez-Rubio, A. S 7-1
 Petersén, B. S 7-2
 Petersen, J. P1-35
 Petersen, J.M. P2-03, P2-60, S 5-1, S 5-2
 Petri, S.E. P1-20
 Pierozzi, C. P2-10
 Piesman, J. P2-03
 Pinson, D.M. S 12-2
 Piper-Hunter, M.G. P2-33
 Pittman, P. P2-57
 Pohlmeier, K. P1-46
 Porter, A. P2-57
 Price, J. P2-65
 Price, J.L. P2-51
 Price, L.B. S 5-1
 Prior, J.L. P1-05

Qin, A. P1-20, S 1-1
 Raghunathan, A. P1-01
 Ramadani, N. P2-14
 Ramakrishnan, G. P1-24
 Randall, T. P2-37
 Rangel-Moreno, J. P2-37
 Ranisch, H. P2-16
 Rasko, D.A. S 6-1
 Rasley, A. P2-01, S 6-2
 Ravneberg, D.H. P2-33
 Ray, H. P2-40, P2-61
 Raymond, C.R. P2-54, S 12-1
 Reese, S.M. P2-03, P2-60
 Reisp, K. P2-05
 Roberts, S.A. P2-43
 Robertson, G.T. S 8-4
 Robison, R. P2-01, S 6-2
 Rodriguez, A.R. S 9-4
 Rodriguez, S.A. P2-62
 Rodríguez-Vargas, M. S 4-3
 Rollo, G. S 4-3
 Roos, N. S 4-1
 Rosenthal, B.M. S 7-4
 Roth, M. S 6-1
 Ruiz Sopena, C. S 7-1
 Ruiz, M. S 4-3
 Runge, M. P1-46
 Rydén, P. P2-32, S 7-2
 Ryder, C. P2-55
 Sáez-Nieto, J.A. S 4-3
 Saint, R.J. P2-30
 Salomonsson, E. P2-47, S 2-4, S 4-1
 Sandström, G. P1-37
 Santic, M. S 10-1
 Santos, N. P2-12
 Sauer, U. P1-36

- Schäfer, M. P2-06, S 7-2
- Schlesinger, L.S. P2-33, S 10-2
- Schmoltdt, S. P1-41
- Scholz, H.C. S 4-4
- Schriefer, M.E. P2-60
- Schuff-Werner, P. S 8-2
- Schulert, G.S. P2-27
- Schulze, C. P1-43, P2-16
- Schwartz, J.T. P2-56
- Scoles, G.A. P1-03
- Scott, D. P1-20
- Scott, D.W. S 1-1
- Seibold, E. P1-17, P1-41, P1-44,
S 4-4, S 5-4, S 8-2
- Seshadri, S. P2-31
- Seshu, J. P2-62
- Seufferlein, T. P1-42
- Sevillano, I. S 7-1
- Shafferman, A. P1-11, P2-46
- Shea, A. P1-16
- Sheldon, S.W. P2-03, P2-60
- Shen, H. P2-54, S 12-1
- Sherwood, R. P2-29, S 11-1
- Sherwood, R.L. P2-49
- Sherwood, R.S. P2-26
- Sheshko, V. P1-30
- Shin, S. P1-01
- Simsek, H. S 4-2
- Sjödin, A. P1-29
- Sjöstedt, A. P2-32, P2-47, S 2-4,
S 7-2, S 8-5
- Sjostedt, A. S 12-1
- Smith Alumni, T. S 12-3
- Smith, S.A. P1-18
- Soares, T. P2-12
- Soni, S. P1-18
- Sparks, G. P2-65
- Sperandio, V. S 6-1
- Spidlova, P. P1-09, P1-30
- Splettstoesser, W. P1-17, P1-41, P1-44,
P1-46, S 4-4, S 5-4, S 8-2
- Spormann, A. P2-01
- Staples, J.E. S 5-2
- Stöven, S. P2-32
- Straskova, A. P1-30
- Stulik, J. P1-07, P1-09, P1-10, P1-12,
P1-30, P1-31, P1-32, P2-48, S 10-5
- Svensson, K. P2-21, S 5-3
- Sweed, A. P1-14
- Taege, C. P1-42
- Taft-Benz, S. P1-22, S 1-3
- Talini, M. P2-10
- Tamames, S. S 7-1
- Taner, M. S 4-2
- Tarwacki, D.M. P2-59
- Taussig, R. S 6-1
- Telford III, S.R. S 7-4
- Thanassi, D.G. P1-08
- Thelaus, J. P2-06
- Thibault, F.M. P1-34
- Thomas, D.P. S 4-5
- Thomas, R.M. P1-05
- Thullier, P. P1-44
- Tináková, K. P2-15
- Titball, R. S 2-4
- Titball, R.W. P1-05
- Tridandapani, S. P2-33, S 10-2
- Tsertsvadze, N. P1-04
- Turnbull, M.W. S 6-3
- Twine, S. S 12-1
- Twine, S.M. P1-05
- Vahaboglu, H. S 4-2
- Vaissaire, J. P1-34, S 5-1
- Valade, E. P1-34
- Valderas, M. S 11-1
- Valderas, M.M. P2-26
- Valderas, M.W. P2-29
- Valentino, M. P2-28
- Van Zandt, K. S 11-2
- Van Zandt, K.E. P2-52, P2-53
- Velan, B. P2-46
- Vian, E. S 7-1
- Vicari, N. P2-10
- Vidal, D.R. P1-34
- Vipond, R. P1-14
- Vladimirova, A. P2-57
- Vogler, A.J. S 5-1
- Voigt, U. P1-46
- von Keyserlingk, M. P1-46
- Výrosteková, V. P2-13, P2-15
- Waag, D. S 11-3
- Wagner, D.M. S 5-1
- Wahab, T. P2-09
- Waldor, M. P1-13
- Wanderlingh, W. P2-10
- Wangxue, C. S 12-1
- Weber, M.V.R. P1-17, P1-41
- Wedekind, M. P1-46
- Wei, S. S 6-1
- Weiner, Z. P1-20
- Weir, S. P2-37
- Weiss, D. S 1-2
- Weiss, D.S. P1-15
- Welch, S. P1-14
- West, M. P2-57
- Wetzler, L.M. P2-37
- Wewers, M.D. P2-31, S 10-2
- White, F.G. P1-18
- Wickstrum, J.R. S 12-2
- Wijayatunga, P. S 7-2
- Wikström, P. S 5-3
- Wilder, J. P2-29
- Wilder, J.A. P2-26, S 11-1
- Williams, N. S 6-1
- Winther-Larsen, H.C. S 4-1
- Wolcott, M. P1-16
- Wolfrain, L. P2-51
- Wolfrain, L.A. P2-65
- Woolard, M. P2-28
- Woolard, M.D. S 8-3
- Wu, T. P2-25, P2-40
- Wu, T.H. P2-44
- Yeh, H.W. S 12-2
- Yockey, B.M. P2-60
- Young, J.W. P2-60
- Yu, J. P2-40, P2-61
- Yu, J.-J. P2-23, P2-62, S 4-5, S 9-4
- Zaide, G. P1-11
- Zakalashvili, M. P1-04
- Zeman, E. S 5-4
- Zé-Zé, L. P2-12
- Zhang, F. P2-11
- Zheng, H. P1-19
- Zhgenti, E. P1-04
- Zingmark, C. P2-47, S 12-1
- Zinter, E. P2-29
- Zivna, L. P2-41



Tularemia



6th IntConfTul 2009

Network